

## Prof. Dr. ABDURRAHİM HALUK ÖZEN

### Kişisel Bilgiler

E-posta: hozhen@hacettepe.edu.tr  
Web: <https://avesis.hacettepe.edu.tr/hozen>

### Eğitim Bilgileri

Tıpta Uzmanlık, Hacettepe Üniversitesi, Tıp Fakültesi, Türkiye 1977 - 1981  
Lisans, Hacettepe Üniversitesi, Tıp Fakültesi, Türkiye 1971 - 1977

### Akademik İdari Deneyim

Hacettepe Üniversitesi, Rektörlük, 2017 - Devam Ediyor  
Hacettepe Üniversitesi, Tıp Fakültesi (İngilizce), Cerrahi Tıp Bilimleri Bölümü, 2004 - 2011  
Hacettepe Üniversitesi, Tıp Fakültesi, 1994 - 1996

### SCI, SSCI ve AHCI İndekslerine Giren Dergilerde Yayınlanan Makaleler

- I. **Ga-68-labelled PSMA ligand HBED-CC PET/CT imaging in patients with recurrent prostate cancer**  
AKDEMİR E., TUNCEL M., AKYOL H. F., BİLEN C. Y., Baydar D. E., KARABULUT E., ÖZEN A. H., Caglar M.  
WORLD JOURNAL OF UROLOGY, cilt.37, sa.5, ss.813-821, 2019 (SCI-Expanded)
- II. **Polyethyleneimine brushes effectively inhibit encrustation on polyurethane ureteral stents both in dynamic bioreactor and in vivo**  
GULTEKINOGLU M., Kurum B., Karahan S., KART D., SAĞIROĞLU M., Ertas N., ÖZEN A. H., ULUBAYRAM K.  
MATERIALS SCIENCE & ENGINEERING C-MATERIALS FOR BIOLOGICAL APPLICATIONS, cilt.71, ss.1166-1174, 2017  
(SCI-Expanded)
- III. **Therapeutic effects of Mycobacterium phlei cell wall extracts**  
ORHAN B., BÜBER E., KESKİN M. S., ÇELİKBIÇAK Ö., SALİH B., ALP A., SARIBAŞ Z., ÖZEN A. H., ACAN N. L.  
TURKISH JOURNAL OF MEDICAL SCIENCES, cilt.42, sa.2, ss.193-199, 2012 (SCI-Expanded)
- IV. **ADT for volume reduction, symptom relief and quality of life improvement in men with prostate cancer: Degarelix versus goserelin plus bicalutamide**  
Axcrona K., Aaltomaa S., Da Silva C. M., Ozen H., Damber J. E., Tanko L. B., Colli E., Klarskov P.  
EUROPEAN UROLOGY SUPPLEMENTS, cilt.11, sa.1, 2012 (SCI-Expanded)
- V. **ROBOTIC RADIOSURGERY IN PROSTATE ADENOCARCINOMA: INITIAL THERAPEUTIC RESULTS AND QUALITY OF LIFE ASSESSMENT**  
Akyol F., Ozigit G., Sanli Y. T., Cengiz M., Akdogan B., YAZICI M. S., Yildiz F., Zorlu F., Gurkaynak M., Dogan A., et al.  
RADIOTHERAPY AND ONCOLOGY, cilt.96, 2010 (SCI-Expanded)
- VI. **Testicular teratoma and anti-N-methyl-D-aspartate receptor-associated encephalitis**  
Eker A., Saka E., Dalmau J., Kurne A., Bilen C., Ozen H., Ertoy D., Oguz K. K., Elibol B.  
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, cilt.79, sa.9, ss.1082-1083, 2008 (SCI-Expanded)
- VII. **Is intermittent docetaxel chemotherapy reasonable in hormone refractory prostate cancer? A prospective randomised study**  
Akdogan B., Ozen H., Kirdal Y.

- EUROPEAN UROLOGY SUPPLEMENTS, cilt.7, sa.3, ss.231, 2008 (SCI-Expanded)
- VIII. **A cadaveric histological investigation of the prostate with three-dimensional reconstruction for better results in continence and erectile function after radical prostatectomy**  
Ozdemir M. B., Eskicorapci S. Y., Baydar D. E., Cumhur M., Onderoglu S., Ozen H.  
PROSTATE CANCER AND PROSTATIC DISEASES, cilt.10, sa.1, ss.77-81, 2007 (SCI-Expanded)
- IX. **A new technique in the treatment of postprostatectomy incontinence: Adjustable male sling**  
Inci K., Ergen A., Yuksel S., Ozen H.  
EUROPEAN UROLOGY SUPPLEMENTS, cilt.6, sa.2, ss.76, 2007 (SCI-Expanded)
- X. **Percutaneous nephrolithotomy in children: Two centers experience with 167 renal units**  
ŞAHİN A., Bilen C. Y., Inci K., Tan B., Eren M., Elhaj S., Sarikaya S., Tekgul S., Ozen H.  
EUROPEAN UROLOGY SUPPLEMENTS, cilt.6, sa.2, ss.243, 2007 (SCI-Expanded)
- XI. **The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: A prospective, randomized clinical trial**  
Divrik R., Yildirim U., Zorlu F., Ozen H.  
JOURNAL OF UROLOGY, cilt.175, sa.5, ss.1641-1644, 2006 (SCI-Expanded)
- XII. **Serum ribonuclease activity in the diagnosis of prostate cancer in men with serum prostate-specific antigen levels between 2.5 and 20 ng/mL**  
ESKICORAPCI S., Ozkara H. A., ONDER E., AKDOGAN B., ERKAN İ., CILIV G., Ozen H.  
CLINICAL BIOCHEMISTRY, cilt.39, sa.4, ss.363-366, 2006 (SCI-Expanded)
- XIII. **Low-grade Ta (noninvasive) urothelial carcinoma of the bladder**  
Oosterlinck W., Solsona E., Akaza H., Busch C., Goebell P., Malmstrom P., Ozen H., Sved P.  
UROLOGY, cilt.66, ss.75-89, 2005 (SCI-Expanded)
- XIV. **Bilateral scrotal extra peritoneal herniation of ureters - Computed tomography urographic findings and review of the literature**  
Akpinar E., Turkbey B., Ozcan O., Akdogan B., KARÇAALTINCABA M., Ozen H.  
JOURNAL OF COMPUTER ASSISTED TOMOGRAPHY, cilt.29, sa.6, ss.790-792, 2005 (SCI-Expanded)
- XV. **Individualization of the biopsy protocol according to the prostate gland volume for prostate cancer detection**  
Eskicorapci S., Guliyev F., Akdogan B., Dogan H., Ergen A., Ozen H.  
JOURNAL OF UROLOGY, cilt.173, sa.5, ss.1536-1540, 2005 (SCI-Expanded)
- XVI. **Can we obtain better specimens with an end-cutting prostatic biopsy device?**  
Dogan H., Eskicorapci S., Ertoy-Baydar D., Akdogan B., Gunay L., Ozen H.  
EUROPEAN UROLOGY, cilt.47, sa.3, ss.297-301, 2005 (SCI-Expanded)
- XVII. **Complexed prostate specific antigen density is better than the other PSA derivatives for detection of prostate cancer in men with total PSA between 2.5 and 20 ng/ml: Results of a prospective multicenter study**  
Sozen S., Eskicorapci S., Kupelia B., Irkilata L., Altinel M., Ozer G., Uygur C., Alkibay T., Ozen H.  
EUROPEAN UROLOGY, cilt.47, sa.3, ss.302-307, 2005 (SCI-Expanded)
- XVIII. **Proliferating-cell nuclear antigen (PCNA) as an Independent prognostic marker in patients after prostatectomy: a comparison of PCNA and Ki-67**  
Taftachi R., Ayhan A., Ekici S., Ergen A., Ozen H.  
BJU INTERNATIONAL, cilt.95, sa.4, ss.650-654, 2005 (SCI-Expanded)
- XIX. **CYP1A1 and GSTM1 polymorphic genotypes in patients with prostate cancer in a Turkish population**  
Aktas D., Hascicek M., Sozen S., Ozen H., Tuncbilek E.  
CANCER GENETICS AND CYTOGENETICS, cilt.154, sa.1, ss.81-85, 2004 (SCI-Expanded)
- XX. **Successful management of chromophobe type renal cell carcinoma in pregnancy**  
Guven S., Guven E., Islamoglu E., Gunalp G., Ozen H.  
AUSTRALIAN & NEW ZEALAND JOURNAL OF OBSTETRICS & GYNAECOLOGY, cilt.44, sa.4, ss.362-363, 2004 (SCI-Expanded)
- XXI. **Resection of pulmonary metastases following chemotherapy for high stage testicular tumors**  
Eskicorapci S., Ekici S., Atsu M., Dogan R., Ozen H.

- International Journal of Urology, cilt.11, sa.8, ss.634-639, 2004 (SCI-Expanded)
- XXII. **An extended 10-core transrectal ultrasonography guided prostate biopsy protocol improves the detection of prostate cancer**  
Eskicorapci S., Baydar D., AKBAL C., Sofikerim M., Gunay M., Ekici S., Ozen H.  
EUROPEAN UROLOGY, cilt.45, sa.4, ss.444-448, 2004 (SCI-Expanded)
- XXIII. **Urinary markers for urothelial cancer**  
Sozen S., Eskicorabci S., Ozen H.  
BJU INTERNATIONAL, cilt.92, sa.6, ss.531-533, 2003 (SCI-Expanded)
- XXIV. **The role of the pathologist in the evaluation of radical prostatectomy specimens**  
Ekici S., Ayhan A., Erkan I., Bakkaloglu M., Ozen H.  
SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY, cilt.37, sa.5, ss.387-391, 2003 (SCI-Expanded)
- XXV. **A novel surveillance protocol for stage I nonseminomatous germ cell testicular tumours**  
Atsu N., Eskicorapci S., ÜNER A., Ekici S., Gungen Y., Erkan I., Uygur M., Ozen H.  
BJU INTERNATIONAL, cilt.92, sa.1, ss.32-35, 2003 (SCI-Expanded)
- XXVI. **Prevalence of lower urinary tract symptoms in a community-based survey of men in Turkey**  
AKI F. T., Aygun C., Bilir N., Erkan I., Ozen H.  
INTERNATIONAL JOURNAL OF UROLOGY, cilt.10, sa.7, ss.364-370, 2003 (SCI-Expanded)
- XXVII. **The predictive value of purified protein derivative results on complications and prognosis in patients with bladder cancer treated with bacillus Calmette-Guerin**  
Bilen C., Inci K., Erkan I., Ozen H.  
JOURNAL OF UROLOGY, cilt.169, sa.5, ss.1702-1705, 2003 (SCI-Expanded)
- XXVIII. **Gynecomastia following chemotherapy for testicular cancer**  
Uygur M., Ozen H.  
UROLOGIA INTERNATIONALIS, cilt.70, sa.3, ss.253-254, 2003 (SCI-Expanded)
- XXIX. **Determination of prognosis in patients with prostate cancer treated with radical prostatectomy: Prognostic value of CD44v6 score**  
Ekici S., Ayhan A., Kendi S., Ozen H.  
JOURNAL OF UROLOGY, cilt.167, sa.5, ss.2037-2041, 2002 (SCI-Expanded)
- XXX. **Surgical management of renal cell carcinoma with inferior vena cava tumor thrombus**  
Kaplan S., Ekici S., Dogan R., Demircin M., Ozen H., Pasaoglu I.  
American Journal of Surgery, cilt.183, sa.3, ss.292-299, 2002 (SCI-Expanded)
- XXXI. **False-positive results of the NMP22 test due to hematuria**  
Atsu N., Ekici S., Oge O., Ergen A., Hascelik G., Ozen H.  
JOURNAL OF UROLOGY, cilt.167, sa.2, ss.555-558, 2002 (SCI-Expanded)
- XXXII. **Microstaging of pT1 transitional cell carcinoma of the bladder - Does it really differentiate two populations with different prognoses? (pT1 subcategory)**  
Sozen S., AKBAL C., Sokmensuer C., Ekici S., Ozen H.  
UROLOGIA INTERNATIONALIS, cilt.69, sa.3, ss.200-206, 2002 (SCI-Expanded)
- XXXIII. **Comparison of BTA stat and NMP22 tests in the detection of bladder cancer**  
Oge O., Atsu N., Sahin A., Ozen H.  
SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY, cilt.34, sa.6, ss.349-351, 2000 (SCI-Expanded)
- XXXIV. **Is scrotal violation per se a risk factor for local relapse and metastases in stage I nonseminomatous testicular cancer?**  
Aki F., Bilen C., Tekin M., Ozen H.  
UROLOGY, cilt.56, sa.3, ss.459-462, 2000 (SCI-Expanded)
- XXXV. **A study of the etiology of idiopathic calcium urolithiasis in children: Hypocitruria is the most important risk factor**  
Tekin A., Tekgul S., Atsu N., Sahin A., Ozen H., Bakkaloglu M.  
JOURNAL OF UROLOGY, cilt.164, sa.1, ss.162-165, 2000 (SCI-Expanded)
- XXXVI. **Induction of mycobacteremia by intravesical bacillus Calmette-Guerin instillation in an experimental animal model and detection with polymerase chain reaction**

- Aygun C., Ozen H., Kocagoz T., Saribas Z., Aki T., Tekin I.  
JOURNAL OF UROLOGY, cilt.163, sa.5, ss.1588-1590, 2000 (SCI-Expanded)
- XXXVII. **Bilateral germ cell cancer of the testis: a report of 11 patients with a long-term follow-up**  
Tekin A., Aygun Y., Aki F., Ozen H.  
BJU INTERNATIONAL, cilt.85, sa.7, ss.864-868, 2000 (SCI-Expanded)
- XXXVIII. **Bladder cancer**  
Ozen H., Hall M.  
CURRENT OPINION IN ONCOLOGY, cilt.12, sa.3, ss.255-259, 2000 (SCI-Expanded)
- XXXIX. **Proposal for changes in cystoscopic follow-up of patients with low-grade pTa bladder tumor**  
Oge O., Erdem E., Atsu N., Sahin A., Ozen H.  
EUROPEAN UROLOGY, cilt.37, sa.3, ss.271-273, 2000 (SCI-Expanded)
- XL. **Marsupialization for bilateral pararenal lymphatic cysts**  
Ekici S., Ziraman I., Ozen H., Erkan I.  
SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY, cilt.34, sa.1, ss.77-78, 2000 (SCI-Expanded)
- XLI. **RETRIEVAL OF BROKEN DOUBLE-J CATHETER BY DORMIA BASKET**  
ERKAN I., SARIYUCE O., OZEN H.  
BRITISH JOURNAL OF UROLOGY, cilt.66, sa.1, ss.107-108, 1990 (SCI-Expanded)

### **Diğer Dergilerde Yayınlanan Makaleler**

- I. **Can p53, Ki-67 and bcl-2 predict biochemical failure after radical prostatectomy?**  
Baseskioglu B., Akdogan B., Baydar D. E., Ozen H.  
INDIAN JOURNAL OF UROLOGY, cilt.26, sa.2, ss.206-212, 2010 (ESCI)

### **Hakemli Kongre / Sempozyum Bildiri Kitaplarında Yer Alan Yayınlar**

- I. **Studies with some mycobacterial culture filtrates for immunotherapeutical activity**  
ERTÜRK Z., BÜBER E., ÖZEN A. H., ÇELİKBIÇAK Ö., SALİH B., AÇAN N. L.  
22th ISE International Conference All Aspects of Laboratory Medicine, 30 Haziran - 03 Temmuz 2018
- II. **PROSTAT KANSERİNİN DEFINİTİF TEDAVİSİ SONRASI REKÜRRENSİNDE GA-68-PSMA PET/BT POZİTİFLİK ORANI VE ETKİ EDEN FAKTORLER**  
AYDIN A. M., HABERAL H. B., Artykov M., AKDOĞAN B., GÜDELOĞLU A., BİLEN C. Y., ERGEN A., YAZICI M. S., ÖZEN A. H.  
13. Üroonkoloji Kongresi, Türkiye, 8 - 12 Kasım 2017
- III. **GA-68 PSMA PET/BT'xxNİN PROSTAT KANSERİ LENF NODU EVRELEMESİİNDEKİ ETKİNLİĞİ: ERKEN DÖNEM SONUÇLAR**  
AYDIN A. M., HABERAL H. B., Artykov M., AKDOĞAN B., GÜDELOĞLU A., BİLEN C. Y., ERGEN A., YAZICI M. S., ÖZEN A. H.  
13. Üroonkoloji Kongresi, Türkiye, 8 - 12 Kasım 2017
- IV. **Designing and Performance of Antibacterial Polymeric Brushed Ureteral Stents In-vivo**  
GULTEKINOGLU M., KART D., KÜRÜM B., AKSOY E. A., KARAHAN S., SAĞIROĞLU M., ÖZEN A. H., ULUBAYRAM K.  
International Biomedical Science and Technology Symposium, Ankara, Türkiye, 12 - 14 Mayıs 2017
- V. **Metastatik kastrasyona dirençli prostat kanser hastalarında kabazitakselin güvenlik verileri:**  
Kabazitaksel Türkiye insani amaçlı ilaca erişim programı sonuçları  
BAVBEK S., BAŞARAN M., ÖZEN A. H., ERMAN M., ÖZDOĞAN M., ÖZGÜROĞLU M., GÖKER E.  
22. ULUSAL KANSER KONGRESİ, Türkiye, 19 - 23 Nisan 2017
- VI. **TOLERABILITY OF CABAZITAXEL IN SENIOR ADULTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) IN EUROPE**  
Heidenreich A., Bracarda S., Mason M., Ozen H., Sengelov L., Gerritsen W., Papandreou C., Fossa S., Hitier S., Climent

- M.
- 37th Congress of the European-Society-for-Medical-Oncology (ESMO), Vienna, Avusturya, 28 Eylül - 02 Ekim 2012,  
cilt.23, ss.307
- VII. **EFFICACY AND TOLERABILITY OF TAXANE-BASED CHEMOTHERAPY IN SENIOR ADULTS WITH  
METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC): A PROSPECTIVE  
INTERNATIONAL REGISTRY**
- Droz J., Efstathiou E., Heidenreich A., Yildirim A., Cabrera P., Kim C., Horchani A., Ozen H., Rinck J. A.  
37th Congress of the European-Society-for-Medical-Oncology (ESMO), Vienna, Avusturya, 28 Eylül - 02 Ekim 2012,  
cilt.23, ss.308
- VIII. **Incidence of EDNRB hypermethylation in prostatic adenocarcinoma**
- Baydar D. E., Himmetoglu C., Ozen H., De Marzo A. M.  
97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology, Colorado, Amerika Birleşik  
Devletleri, 1 - 07 Mart 2008, cilt.21
- IX. **Lymphovascular invasion in prostatic adenocarcinoma**
- Ertoy-Baydar D., Baseskioglu B., Ozen H., Geyik P.  
96th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology, California, Amerika Birleşik  
Devletleri, 24 - 30 Mart 2007, cilt.20
- X. **Immunohistochemical analysis of PTEN expression in radical prostatectomies**
- Ertoy-Baydar D., Ozen H., Saracbasi O., De Marzo A. M.  
96th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology, California, Amerika Birleşik  
Devletleri, 24 - 30 Mart 2007, cilt.87
- XI. **Telomere shortening correlates with short relapse-free survival time in prostate adenocarcinoma**
- Ertoy-Baydar D., Ozen H., Gurel B., Saracbasi O., Geyik P., De Marzo A. M.  
96th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology, California, Amerika Birleşik  
Devletleri, 24 - 30 Mart 2007, cilt.20

## Metrikler

Yayın: 54  
Atıf (WoS): 998  
Atıf (Scopus): 136  
H-İndeks (WoS): 19  
H-İndeks (Scopus): 4